CA
NZ
UK
AU
IND
US
• The stock jumped over 9% in the prior session on the trial dosing news.
• The company will sell 4,380,313 shares in a registered direct offering.
• The company amended its merger agreement with InnocsAI LLC.
• Second-quarter 2026 earnings call is scheduled for August 4.
• The company raised $3.5 million in a private placement priced at $5.91 per share, with milestone-based warrants attached.
• EVMN shares fell 1.39% intraday to $13.11 after the company reported Phase 2b trial results for EVO756.
• The company announced its Q2 2026 earnings call is scheduled for July 29.
• The company submitted software enhancements for its Pivot tubeless insulin patch pump to the FDA.
• The company closed its $100 million public offering, priced at $20.00 per share.
• The one-for-six reverse split became effective June 29, reducing shares outstanding to approximately 888,592.
Please wait processing your request...